Supplementary Materials

**Table S1.** Evolution profile of TJC, SJC, serum CRP and ESR levels and concomitant use of DMARDs and corticosteroids at baseline, at 26 and 52 weeks after the initiation and comparison between ETN and GP2015 groups.

|                | ETN (n=90) | GP2015 (n=25) | Total (n=115) | p-value |
|----------------|------------|---------------|---------------|---------|
| **TJC**        |            |               |               |         |
| Baseline       | 9.0 (7.9)  | 8.6 (6.6)     | 8.9 (7.6)     | 0.711   |
| At 26 weeks    | 1.2 (3.0)  | 1.8 (4.1)     | 1.3 (3.3)     | 0.561   |
| At 52 weeks    | 1.6 (3.2)  | 1.4 (2.3)     | 1.6 (2.9)     | 0.824   |
| **SJC**        |            |               |               |         |
| Baseline       | 8.9 (7.4)  | 6.8 (5.0)     | 8.4 (7.0)     | **0.037** |
| At 26 weeks    | 1.4 (2.7)  | 1.8 (2.9)     | 1.5 (2.7)     | 0.662   |
| At 52 weeks    | 1.5 (2.8)  | 1.4 (2.1)     | 1.5 (2.7)     | 0.892   |
| **CRP serum levels (mg/dL)** |            |               |               |         |
| Baseline       | 1.7 (2.5)  | 0.8 (0.7)     | 1.5 (2.2)     | **0.011** |
| At 26 weeks    | 0.8 (1.6)  | 0.4 (0.6)     | 0.7 (1.5)     | 0.408   |
|                          | At 52 weeks |     |     |     |
|--------------------------|-------------|-----|-----|-----|
|                          | 0.5 (0.8)   | 0.3 (0.5) | 0.5 (0.7) | 0.568 |

**ESR serum levels (mm/h)**

|                          | Baseline |     |     |     |
|--------------------------|----------|-----|-----|-----|
|                          | 26.7 (20.6) | 25.4 (21.6) | 26.4 (20.7) | 0.728 |
|                          | At 26 weeks |     |     |     |
|                          | 18.7 (17.2) | 14.0 (14.2) | 17.7 (16.7) | 0.236 |
|                          | At 52 weeks |     |     |     |
|                          | 18.4 (16.4) | 11.8 (15.6) | 16.9 (16.3) | 0.089 |

**Concomitant DMARDs**

|                          | Baseline |     |     |     |
|--------------------------|----------|-----|-----|-----|
|                          | 69 (78.4) | 19 (76.0) | 88 (77.9) | 0.798 |
|                          | At 26 weeks |     |     |     |
|                          | 56 (70.9) | 13 (59.1) | 69 (68.3) | 0.544 |
|                          | At 52 weeks |     |     |     |
|                          | 50 (69.4) | 13 (59.1) | 63 (67.0) | 0.605 |

**Concomitant corticosteroids**

|                          | Baseline |     |     |     |
|--------------------------|----------|-----|-----|-----|
|                          | 65 (72.2) | 7 (28.0) | 72 (62.6) | <0.001 |
|                          | At 26 weeks |     |     |     |
|                          | 45 (55.6) | 6 (27.3) | 51 (49.5) | 0.012 |
|                          | At 52 weeks |     |     |     |
|                          | 36 (48.6) | 4 (18.2) | 40 (41.7) | 0.009 |

Data presented as mean (SD) and n (%). ETN etanercept original (Enbrel®), GP2015 etanercept biosimilar (Erelzi®), TJC tender joint count, SCJ swollen joint count, CRP c-reactive protein, ESR erythrocyte sedimentation rate, DMARDs disease
modifying antirheumatic drugs. The differences observed in the baseline p-values compared to Table 1 are derived from the longitudinal statistical analysis used.

**Table S2.** Reported adverse events leading to discontinuation in the ETN and GP2015 groups.

| Adverse events                        | ETN, n=90 | GP2015, n=25 |
|---------------------------------------|-----------|--------------|
| Total                                 | 7 (7.8)   | 1 (4.0)      |
| Injection site reactions              | 1 (1.1)   | 0 (0.0)      |
| Upper respiratory tract infection     | 1 (1.1)   | 0 (0.0)      |
| Urticaria                             | 2 (2.2)   | 0 (0.0)      |
| Hepatotoxicity                        | 1 (1.1)   | 0 (0.0)      |
| Thrombocytopenia                      | 1 (1.1)   | 0 (0.0)      |
| Pneumonia                             | 1 (1.1)   | 0 (0.0)      |
| Flu-like syndrome                     | 0 (0.0)   | 1 (4.0)      |

Data presented as n (%). ETN etanercept original (Enbrel®), GP2015 etanercept biosimilar (Erelzi®)

**Figure S1.** Mean change from baseline over 52 weeks in **a)** TJC **b)** SJC **c)** CRP **d)** ESR scores of ETN and GP2015 cohorts.

ETN etanercept original (Enbrel®), GP2015 etanercept biosimilar (Erelzi®), TJC number of tender joints, SJC number of swollen joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate,

**a)** TJC (p-value=0.679)

**b)** SJC (p-value=0.209)
c) CRP (p-value=0.190)

d) ESR (p-value=0.251)